BioLamina’s core innovation lies in its proprietary laminins—highly specialized proteins that replicate the natural environment in which human cells grow.
BioLamina secures a €20M EIB loan to expand its laminin protein technologies used in stem cell therapies and animal-free drug ...
- Financing to accelerate development of rapid testing system to improve infectious disease diagnosis and antibiotics stewardship - Automated phenotypic testing, revolutionizing infectious diseases ...
REHOVOT, Israel, May 12, 2022 /PRNewswire/ -- Research and development of fully automated testing of bacteria and infectious diseases by POCARED Diagnostics will be accelerated by EUR 22 million of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results